Lanadelumab

拉那利尤单抗

Report date: 2026/04/30 20:00:20

Base Information

Drug NameLanadelumab
Drug Alias NameLanadelumab-flyo拉那鲁单抗拉那芦人单抗Anti-plasma kallikrein monoclonal antibodyAnti-plasma kallikrein mAb +[17] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionPlasma kallikrein inhibitors
TargetsPlasma kallikrein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Hereditary Autoinflammatory DiseasesAngioedemas, Hereditary +[5] 
Global Approved IndicationsAngioedemas, Hereditary
Approved Indications in ChinaAngioedemas, Hereditary
Original Approved Country/TerritoryUnited States
Original Approved Date2018/08/23
Country/TerritoryCanadaUnited StatesPoland +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesDyax Pharma
China Registration ClassN/A

Develop Information

Active CompaniesShireSt. Vincent'S Institute Of Medical ResearchTakeda Pharmaceuticals International AG Ireland Branch +[8] 
Inactive CompaniesRadboud University Medical CenterSharp CorpBaishen Biotechnology (Shanghai) Co Ltd
Active IndicationsHereditary Autoinflammatory DiseasesAngioedemas, HereditaryAngioedema +[4] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeB06AC05
Related LinksWikipediaDrugBankKEGG